Literature DB >> 12209601

Heregulin inhibits proliferation via ERKs and phosphatidyl-inositol 3-kinase activation but regulates urokinase plasminogen activator independently of these pathways in metastatic mammary tumor cells.

Lydia Puricelli1, Cecilia J Proietti, Cecilia J Proiettii, Leticia Labriola, Mariana Salatino, María E Balañá, Julio Aguirre Ghiso, Ruth Lupu, Omar P Pignataro, Eduardo H Charreau, Elisa Bal de Kier Joffé, Patricia V Elizalde.   

Abstract

Heregulin (HRG) and type I receptor tyrosine kinase (RTK) expression was investigated in the highly invasive and metastatic LM3 cell line, our previously described model of metastasis for mammary cancer (Bal de Kier Joffe et al. [1986] Invasion Metastasis 6:302-12; Urtreger et al. [1997] Int J Oncol 11:489-96). Although LM3 cells do not express HRG, they exhibit high levels of ErbB-2 and ErbB-3 as well as moderate expression of ErbB-4. Addition of exogenous HRGbeta1 resulted in inhibition of both proliferation and migration of LM3 cells. HRGbeta1 was also able to decrease the activity of urokinase-type plasminogen activator (uPA) and matrix metalloproteinase 9 (MMP-9), 2 key enzymes in the invasion and metastatic cascade. HRGbeta1 treatment of LM3 cells induced tyrosine phosphorylation of ErbB-2, ErbB-3 and ErbB-4 as well as the formation of ErbB-2/ErbB-3 and ErbB-2/ErbB-4 heterodimers. Assessment of the signaling pathways involved in HRGbeta1 action indicated that the addition of HRGbeta1 to LM3 cells resulted in activation of phosphatidylinositol 3- kinase (PI-3K) and in strong induction of the association of the p85 subunit of PI-3K with ErbB-3. HRGbeta1 also caused the rapid activation of ERK1/ERK2 and Stat3 and Stat5 (signal transducers and activators of transcription [STAT]). This is the first demonstration of the ability of HRGbeta1 to activate STATs in mammary tumor cells. Blockage of PI-3K activity with its chemical inhibitor wortmannin, or of MEK1/ERKs activity with PD98059, resulted in suppression of the ability of HRGbeta1 to inhibit LM3 cell growth. Notwithstanding the suppression of these 2 signaling pathways, HRGbeta1 still proved capable of inhibiting uPA activity. Therefore, our results provide evidence that signaling pathways involved in HRGbeta1-induced proliferation appear to be distinct from those involved in HRGbeta1 regulation of uPA, a protease that plays a pivotal role in invasion and metastasis. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12209601     DOI: 10.1002/ijc.10533

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  12 in total

1.  Phosphorylation of ErbB4 on Tyr1056 is critical for inhibition of colony formation by prostate tumor cell lines.

Authors:  Richard M Gallo; Ianthe Bryant; Rachael Fry; Eric E Williams; David J Riese
Journal:  Biochem Biophys Res Commun       Date:  2006-08-18       Impact factor: 3.575

2.  Progestins induce transcriptional activation of signal transducer and activator of transcription 3 (Stat3) via a Jak- and Src-dependent mechanism in breast cancer cells.

Authors:  Cecilia Proietti; Mariana Salatino; Cinthia Rosemblit; Romina Carnevale; Adalí Pecci; Alberto R Kornblihtt; Alfredo A Molinolo; Isabel Frahm; Eduardo H Charreau; Roxana Schillaci; Patricia V Elizalde
Journal:  Mol Cell Biol       Date:  2005-06       Impact factor: 4.272

3.  Decorin, erythroblastic leukaemia viral oncogene homologue B4 and signal transducer and activator of transcription 3 regulation of semaphorin 3A in central nervous system scar tissue.

Authors:  Kenneth H Minor; Juan C Bournat; Nicole Toscano; Roman J Giger; Stephen J A Davies
Journal:  Brain       Date:  2010-11-28       Impact factor: 13.501

Review 4.  Roles for neuregulins in human cancer.

Authors:  Christophe Stove; Marc Bracke
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

5.  Stat3 regulates ErbB-2 expression and co-opts ErbB-2 nuclear function to induce miR-21 expression, PDCD4 downregulation and breast cancer metastasis.

Authors:  L Venturutti; L V Romero; A J Urtreger; M F Chervo; R I Cordo Russo; M F Mercogliano; G Inurrigarro; M G Pereyra; C J Proietti; F Izzo; M C Díaz Flaqué; V Sundblad; J C Roa; P Guzmán; E D Bal de Kier Joffé; E H Charreau; R Schillaci; P V Elizalde
Journal:  Oncogene       Date:  2015-07-27       Impact factor: 9.867

6.  Text mining of full-text journal articles combined with gene expression analysis reveals a relationship between sphingosine-1-phosphate and invasiveness of a glioblastoma cell line.

Authors:  Jeyakumar Natarajan; Daniel Berrar; Werner Dubitzky; Catherine Hack; Yonghong Zhang; Catherine DeSesa; James R Van Brocklyn; Eric G Bremer
Journal:  BMC Bioinformatics       Date:  2006-08-10       Impact factor: 3.169

7.  Neuregulin-1 (Nrg1) signaling has a preventive role and is altered in the frontal cortex under the pathological conditions of Alzheimer's disease.

Authors:  Qiong Jiang; Shuangxi Chen; Chengliang Hu; Peizhi Huang; Huifan Shen; Weijiang Zhao
Journal:  Mol Med Rep       Date:  2016-07-25       Impact factor: 2.952

8.  Mouse mammary tumors display Stat3 activation dependent on leukemia inhibitory factor signaling.

Authors:  Ana Quaglino; Carolina Schere-Levy; Leonardo Romorini; Roberto P Meiss; Edith C Kordon
Journal:  Breast Cancer Res       Date:  2007       Impact factor: 6.466

9.  HER Specific TKIs Exert Their Antineoplastic Effects on Breast Cancer Cell Lines through the Involvement of STAT5 and JNK.

Authors:  Daphne Gschwantler-Kaulich; Thomas W Grunt; Daniela Muhr; Renate Wagner; Heinz Kölbl; Christian F Singer
Journal:  PLoS One       Date:  2016-01-06       Impact factor: 3.240

10.  Differential changes in Neuregulin-1 signaling in major brain regions in a lipopolysaccharide-induced neuroinflammation mouse model.

Authors:  Zhai Yang; Qiong Jiang; Shuang-Xi Chen; Cheng-Liang Hu; Hui-Fan Shen; Pei-Zhi Huang; Jun-Ping Xu; Jin-Ping Mei; Ben-Ping Zhang; Wei-Jiang Zhao
Journal:  Mol Med Rep       Date:  2016-05-23       Impact factor: 2.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.